Advent of artificial blood has eliminate the dependency on donor blood supplies
Synthetic blood is manufactured
by mixing synthetic hemoglobin with water and electrolytes. After completing
the manufacturing process, the blood is pasteurized and packaged. Throughout
the process, the compounds are tested for quality. During the production
process, frequent checks are made on the culture of the bacteria and various
physical and chemical properties of the finished product. Today, there are
factories that can produce large batches of artificial blood.
According to Coherent Market Insights the Artificial
Blood Market Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2022-2028
One of the biggest benefits of
artificial blood is its lack of dependency on donor blood supplies. Its
universal blood group O negative characteristics help it avoid the problems
associated with donor blood, such as shelf life. While donor blood can be
stored for as long as 42 days before being used, it starts to lose quality soon
after collection. Another benefit is that it does not require any biological
materials. Its ability to dissolve more oxygen than blood plasma is what makes
it attractive for use in the emergency situation. As perfluorocarbons are biologically
inert, they are cheaper to produce. This also eliminates any risk of
transmission of infectious diseases. However, despite the benefits of synthetic
blood, these products still have a long way to go. There are two different
types currently under research.
Until recently, the use of animal
blood was not widely used in emergency situations. Originally, doctors used
animal plasma and hemoglobin for blood transfusions. However, this approach
proved to be ineffective, due to several technological issues. Scientists found
it difficult to extract large amounts of hemoglobin and animal products were
contaminated with toxic materials. As such, blood transfusions with animal
products have never gained wide appeal. However, many scientists believe that
artificial blood will be the next step in saving lives. Moreover, the cost of
recombinant hemoglobin is too expensive to match that of blood-derived
hemoglobin. Once the strains are optimized, however, they can be produced at a
large scale. This means that synthetic biotechnology can contribute to further
improvements in this field.
Comments
Post a Comment